Liquaemin en es it fr

Liquaemin Brand names, Liquaemin Analogs

Liquaemin Brand Names Mixture

  • No information avaliable

Liquaemin Chemical_Formula

(C26H40N2O36S5)n

Liquaemin RX_link

http://www.rxlist.com/cgi/generic/heparin.htm

Liquaemin fda sheet

Liquaemin FDA

Liquaemin msds (material safety sheet)

Liquaemin MSDS

Liquaemin Synthesis Reference

No information avaliable

Liquaemin Molecular Weight

12000-15000 g/mol

Liquaemin Melting Point

No information avaliable

Liquaemin H2O Solubility

Soluble

Liquaemin State

Solid

Liquaemin LogP

No information avaliable

Liquaemin Dosage Forms

Solution for subcutaneous injection; Intravenous injection; Intravenous infusion

Liquaemin Indication

For anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension, for prevention of post-operative deep venous thrombosis and pulmonary embolism and for the prevention of clotting in arterial and cardiac surgery.

Liquaemin Pharmacology

Heparin is a highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Heparin is a well known and commonly used anticoagulant which has antithrombotic properties. Heparin is indicated for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, and also for the prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin. Heparin inhibits reactions that lead to the clotting of blood and the formation of fibrin clots both in vitro and in vivo. Heparin acts at multiple sites in the normal coagulation system. Small amounts of Heparin in combination with antithrombin III (Heparin cofactor) can inhibit thrombosis by inactivating activated Factor X and inhibiting the conversion of prothrombin to thrombin. Once active thrombosis has developed, larger amounts of heparin can inhibit further coagulation by inactivating thrombin and preventing the conversion of fibrinogen to fibrin. Heparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor.

Liquaemin Absorption

Some oral absorption but lack of anticoagulant effect. Rapidly taken up by endothelial cells with remainder bound to plasma proteins.

Liquaemin side effects and Toxicity

Heparin sodium - Mouse, median lethal dose greater than 5000 mg/kg. Another side effect is heparin induced thrombocytopenia (HIT syndrome). HIT is caused by an immunological reaction that makes platelets form clots within the blood vessels, thereby using up coagulation factors

Liquaemin Patient Information

No information avaliable

Liquaemin Organisms Affected

Humans and other mammals